Savvy Wealth
Savvy Wealth gives independent financial advisors an operating platform that combines practice tools, investment support and AI-assisted client work.
$100MSeries C
ParticipantAV
Alumni Ventures
Activity from announced rounds
Activity in this selectionUnited States · Oct 9, 2026 · Sep 10, 2026
Alumni Ventures co-invests in startup rounds alongside an established lead investor. Its principal focus is pre-seed through Series B, with typical investments of $1 million to $3 million.
The firm generally joins on the lead investor’s terms, does not take a board seat and commits after a lead is secured. Founders do not need an alumni connection to qualify. This makes it a potential syndicate participant for a company that already has the core terms and leadership of its round in place.
Its platform team works on introductions to customers, hires and subsequent investors. Founders can request help through their investment team or the AVP Hub, including access to the firm’s alumni networks and commercial resources.
Sources
- Rounds participated in
- 8
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 7 First participation on record · 1 follow-on
- Funding in participating rounds
- $304.5M 8 disclosed · full round size, not this investor’s share
By stage
By primary sector
1 more
Healthtech1
By country
Rounds
8 in this selectionMona
Helps small businesses find grants, loans and government funding, prepare applications and access financial coaching.
$3.5MOversubscribed round
ParticipantAmerican Supercritical
American Supercritical develops modular power equipment that converts waste heat into electricity using supercritical carbon dioxide.
$8MPre-seed
ParticipantFootprint
An agentic risk and compliance platform that helps financial institutions investigate cases and run KYC, sanctions and monitoring policies with an auditable record.
$25MSeries B
ParticipantTeRAM
A semiconductor company developing custom three-dimensional SRAM memory to increase bandwidth and capacity for AI computing chips.
$37MFunding
ParticipantRegCell, Inc.
RegCell is developing cell therapies for autoimmune disease by epigenetically reprogramming pathogenic conventional T cells into stable regulatory T cells, aiming to restore immune tolerance without gene engineering; its platform is advancing toward clinical development.
$44MSeries A
ParticipantEvvy
Evvy combines at-home vaginal microbiome testing with clinician-reviewed results, personalized next steps and optional treatment and coaching for women’s health.
$40MSeries B
ParticipantLightfield
Lightfield is an AI-native CRM that builds a shared, continuously updated record of a company's customers for employees and agents.
$47MSeries A
Participant